Researchclopedia

Research Researchers Institutions Topics Submit About

Command Palette

Search for a command to run...

Researchclopedia

Research Researchers Institutions About

© 2026 Researchclopedia. Powered by OpenAlex under CC0 license.

Bristol-Myers Squibb (Japan) | Researchclopedia

Back to institutions

Bristol-Myers Squibb (Japan)

Tokyocompany

556

Works

52,927

Citations

116

h-index

Top Research Topics

Cancer Immunotherapy and Biomarkers Hepatitis C virus research Chronic Lymphocytic Leukemia Research

Top Researchers

Aldons J. Lusis University of California, Los Angeles

956 works105,299 citationsh-index: 145

Recent Research

Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trial

T.K. Choueiri,L. Albigès,et al.

20261 citations

Rheumatoid Arthritis Research and Therapies

Lymphoma Diagnosis and Treatment

Liver Disease Diagnosis and Treatment

Microbial Natural Products and Biosynthesis

Cancer Treatment and Pharmacology

Monoclonal and Polyclonal Antibodies Research

Hepatitis B Virus Studies

HIV/AIDS drug development and treatment

Atrial Fibrillation Management and Outcomes

Guillermo Garcia‐Manero The University of Texas MD Anderson Cancer Center

2,926 works89,196 citationsh-index: 149

Jon Clardy Boston Biomedical Research Institute

1,381 works78,464 citationsh-index: 137

715 works64,060 citationsh-index: 131

Michael Bauer Loyola University Medical Center

1,076 works61,041 citationsh-index: 91

Michael C. Fishbein University of California, Los Angeles

899 works55,914 citationsh-index: 121

A Minimum 3‐Year Follow‐Up of Nivolumab‐Plus‐Ipilimumab in Japanese Patients With Advanced or Metastatic Renal Cell Carcinoma: A Final Analysis of the J‐ <scp>ENCORE</scp> Study

Shuzo Hamamoto,Masahiro Nozawa,et al.

20260 citations

Refined Modulation of Natural Killer Cells by Transforming Growth Factor‐β Isoforms

Kaku Goto,Ryo Amano,et al.

20260 citations

Abstract PS5-03-09: Trial in progress: A phase 2/3 trial of iza-bren (BMS986507/BL-B01D1), an EGFRxHER3 antibody-drug conjugate, vs standard-of-care chemotherapy in patients with previously untreated, locally advanced, recurrent inoperable, or metastatic triple negative breast cancer ineligible for anti-PD-(L)1 treatment (IZABRIGHT-Breast01)

S. Loi,G. Werutsky,et al.

20260 citations

EZClust: A Robust Machine Learning-Based Powder X-Ray Diffraction and Raman Cluster Analysis Model for Efficient High-Throughput Crystallization Polymorph Screening

Zhiwei Yin,Victor W. Rosso,et al.

20260 citations

Anti-drug Antibody Validation Testing and Reporting Harmonization Addendum

Heather Myler,Johanna Mora,et al.

20261 citations